Business Description
Shandong Sinobioway Biomedicine Co Ltd
NAICS : 325998
SIC : 2899
ISIN : CNE1000012Y5
Share Class Description:
SZSE:002581: Class ACompare
Compare
Traded in other countries / regions
002581.China IPO Date
2011-05-20Description
Shandong Sinobioway Biomedicine Co Ltd is engaged in the research, development, manufacturing and marketing of trimethyl orthoformate and triethyl orthoformate.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.48 | |||||
| Equity-to-Asset | 0.91 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.04 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 48.51 | |||||
| Beneish M-Score | -2.7 | |||||
| WACC vs ROIC | ||||||
Growth Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 15.7 | |||||
| 3-Year EBITDA Growth Rate | -26.1 | |||||
| 3-Year EPS without NRI Growth Rate | -20.5 | |||||
| 3-Year FCF Growth Rate | 6.1 | |||||
| 3-Year Book Growth Rate | -0.8 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 24.7 | |||||
| 9-Day RSI | 36.24 | |||||
| 14-Day RSI | 43.24 | |||||
| 6-1 Month Momentum % | -27.5 | |||||
| 12-1 Month Momentum % | -31.45 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.7 | |||||
| Quick Ratio | 5.58 | |||||
| Cash Ratio | 2.84 | |||||
| Days Inventory | 377.11 | |||||
| Days Sales Outstanding | 118.3 | |||||
| Days Payable | 203.51 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | 1.14 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 80.49 | |||||
| Operating Margin % | -37.39 | |||||
| Net Margin % | -77.32 | |||||
| FCF Margin % | 2.28 | |||||
| ROE % | -15.12 | |||||
| ROA % | -13.12 | |||||
| ROIC % | -7.37 | |||||
| ROC (Joel Greenblatt) % | -45.48 | |||||
| ROCE % | -12.74 | |||||
| Years of Profitability over Past 10-Year | 6 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shiller PE Ratio | 62 | |||||
| PS Ratio | 18.67 | |||||
| PB Ratio | 4 | |||||
| Price-to-Tangible-Book | 4.22 | |||||
| Price-to-Free-Cash-Flow | 775 | |||||
| EV-to-EBIT | -26.63 | |||||
| EV-to-EBITDA | -26.63 | |||||
| EV-to-Revenue | 18.35 | |||||
| EV-to-FCF | 803.04 | |||||
| Price-to-Projected-FCF | 8.27 | |||||
| Price-to-Median-PS-Value | 1.22 | |||||
| Price-to-Net-Current-Asset-Value | 27.56 | |||||
| Price-to-Net-Cash | 1240 | |||||
| Earnings Yield (Greenblatt) % | -3.76 | |||||
| FCF Yield % | 0.12 | |||||
| Forward Rate of Return (Yacktman) % | 8.91 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers